Ozge Saritas

Ozge Saritas

Auto-generated profile, based on publicly available information

Ozge Saritas

Department of Ophthalmology, Ankara Yildirim Beyazit University Faculty of Medicine, Ankara, Türkiye

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2024 in Cutaneous and Ocular Toxicology
Verified
Journal Article
Closed access
YTYelda Yildiz Tasci
Yelda Yildiz Tasci
MIMehmet Icoz
Mehmet Icoz
SISule Gokcek Gurturk Icoz
Sule Gokcek Gurturk Icoz
OSOzge Saritas
Ozge Saritas
MYMucella Arikan Yorgun
Mucella Arikan Yorgun
YTYasin Toklu
Yasin Toklu
To determine the effects of the first-dose administration of the Sinovac vaccine on the retina, choroid, and optic disc in healthy participants. This prospective design study was conducted with 27 healthy healthcare workers who received the first dose of Sinovac vaccine and 25 healthy controls who were not vaccinated. In the vaccinated group, ophthalmological examinations and measurements were performed before vaccination and one week and one month after vaccination. Subfoveal, nasal, and temporal choroidal thicknesses (CTs), retinal nerve fiber layer (RNFL) thickness, and macular thickness (MT) were determined using spectral domain-optical coherence tomography at all visits. Superficial, deep, and peripapillary radial capillary plexus (superficial capillary plexus, deep capillary plexus (DCP), and radial peripapillary capillary, respectively), choriocapillaris vascular density, and foveal avascular zone parameters were measured on optical coherence tomography-angiography (OCT-A). No significant difference was detected between the two groups in terms of the parameters measured by OCT and OCT-A (p > 0.05 for all). The CT values measured in all quadrants were significantly higher at the first week after vaccination (p < 0.05 for all), and they returned to their pre-vaccination values at the first month post-vaccination measurement (p > 0.05 for all). Concerning the RNFL and MT values, there was no significant difference between the pre-vaccination and post-vaccination first-week measurements (p > 0.05 for all), but a statistically significant increase was detected in the post-vaccination first-month MT and RNFL measurements (p < 0.05 for all). Only the decreases in the foveal DCP and choriocapillaris vascular density values were significant at the first week after vaccination (p < 0.05 for all). The early changes detected after vaccination in this study suggest the possibility that autoimmune, vascular, and inflammatory diseases may simultaneously emerge in the early post-vaccination period or may be triggered after vaccination, or that the vaccine may unmask these diseases.

22 September 2026 in BMC Ophthalmology
Verified
Journal Article
Open access
PDF file
OSOzge Saritas
Ozge Saritas
ESElif Sahin
Elif Sahin
YTYelda Yildiz Tasci
Yelda Yildiz Tasci
YTYasin Toklu
Yasin Toklu
Background: Vitrectomy with epiretinal membrane (ERM) and internal limiting membrane (ILM) peeling may provide anatomical and functional benefit in selected eyes with refractory diabetic macular edema, but predictors of postoperative outcome remain incompletely defined. This study aimed to evaluate the anatomical and functional outcomes of pars plana vitrectomy (PPV) combined with ERM and ILM peeling in eyes with diabetic macular edema (DME) and to investigate the prognostic value of preoperative OCT biomarkers for postoperative outcomes. Methods: Thirty eyes of 30 patients with DME refractory to repeated intravitreal anti-VEGF and/or corticosteroid therapy underwent 25-gauge PPV with ERM and ILM peeling. Best-corrected visual acuity (BCVA), central subfield thickness (CST), postoperative treatment requirement, and preoperative OCT biomarkers were evaluated. Associations between baseline OCT biomarkers and 12-month anatomical and functional outcomes were assessed using unadjusted analyses and multivariable regression models. Results: Mean BCVA improved from 1.08 ± 0.52 logMAR at baseline to 0.65 ± 0.42 logMAR at 12 months ( P < 0.001), while mean CST decreased from 533.80 ± 100.31 μm to 261.23 ± 34.31 μm ( P < 0.001). Baseline DRIL was independently associated with worse 12-month BCVA (β = 0.399, 95% CI 0.035–0.762; P = 0.032). Eyes with intact EZ showed greater numerical visual improvement than those with EZ disruption, although the difference was not statistically significant ( P = 0.093). Absence of baseline HRF was associated with greater CST reduction in the unadjusted analysis ( P < 0.001), but HRF was not independently associated with 12-month CST ( P = 0.309). During postoperative follow-up, 22 eyes (73.3%) required no additional intravitreal treatment. Conclusions: PPV with ERM and ILM peeling was associated with significant anatomical and functional improvement in selected eyes with refractory DME. Among the preoperative OCT biomarkers evaluated, DRIL showed the most consistent prognostic association with postoperative visual outcome. Preoperative assessment of retinal microstructure may provide complementary information for visual prognostication and patient counseling.

9 November 2026 in BMC Ophthalmology
Verified
Journal Article
Open access
PDF file
OSOzge Saritas
Ozge Saritas
MAMelih Akyüz
Melih Akyüz
EGEsra Yigit Gokpinar
Esra Yigit Gokpinar
YTYelda Yildiz Tasci
Yelda Yildiz Tasci
YTYasin Toklu
Yasin Toklu
Background: Repeated intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections raise concern about systemic arterial thromboembolic events. We evaluated the cumulative incidence of first thromboembolic events, associated factors, and the association of incident events with all-cause mortality in a treated cohort. Methods: This single-centre retrospective cohort study included 321 patients who initiated intravitreal therapy for neovascular age-related macular degeneration, diabetic macular edema, or retinal vein occlusion between April 2019 and April 2025 and were followed until September 2026. The primary outcome was the first myocardial infarction or ischemic stroke. Cumulative incidence was estimated with the Aalen–Johansen method, treating death as a competing event. Associated factors were evaluated with cause-specific Cox models with a time-updated cumulative number of injections and covariates selected a priori. Mortality was assessed with time-dependent Cox regression, with a sensitivity analysis excluding same-day deaths. Results: During a median follow-up of 45.6 months, 28 patients (8.7%) had a first arterial thromboembolic event (myocardial infarction, 16; ischemic stroke, 12). The competing-risk cumulative incidence was 2.1%, 5.7%, 8.5%, and 10.1% at 12, 24, 36, and 48 months, respectively. Time-updated cumulative injection count was not significantly associated with the cause-specific hazard of thromboembolic events (hazard ratio 1.06 per five injections; 95% confidence interval 0.84–1.34). Diabetes mellitus had an imprecise association in the primary model (hazard ratio 3.18; 95% confidence interval 0.79–12.77) that was statistically significant in two sensitivity models. Diabetes duration, baseline glycated hemoglobin, and time-updated bilateral treatment were not significantly associated with thromboembolic events. Incident arterial thromboembolic events were associated with higher all-cause mortality (adjusted HR 10.61; 95% CI 3.95–28.47), with the association remaining elevated in sensitivity analysis (adjusted HR 3.80; 95% CI 1.29–11.18). Conclusions: In this treated cohort, the four-year cumulative incidence of a first arterial thromboembolic event was approximately 10%. No significant association with time-updated cumulative injection count was detected, although clinically important associations cannot be excluded. Incident arterial thromboembolic events were associated with higher all-cause mortality, and this association persisted in sensitivity analysis. Without an untreated comparator, these findings cannot establish cardiovascular safety or harm attributable to intravitreal anti-VEGF therapy. Trial registration: Not applicable.

13 November 2026 in International Ophthalmology
Verified
Journal Article
Closed access
OSOzge Saritas
Ozge Saritas
PDPiraye Dundar
Piraye Dundar
EGEsra Yigit Gokpinar
Esra Yigit Gokpinar
YTYelda Yildiz Tasci
Yelda Yildiz Tasci
YTYasin Toklu
Yasin Toklu

5 October 2024 in Güncel Retina Dergisi (Current Retina Journal)
Verified
Journal Article
Open access
PDF file
ÖSÖzge Saritaş
Özge Saritaş
YTYasin Toklu
Yasin Toklu
Comparing the ocular anatomy of children and adults, there are certain dimensions and structural differences. A safer surgical method is made possible by an understanding of the major distinctions between the eyes of children and adults,and specific evaluations are required. The primary distinctions are in the locations of sclerotomies, the requirement for posterior hyaloid separation and total vitrectomy, endo-tamponade, and the surgical technique according to the vitreoretinal disease. We tried to summarize the main differences in pediatric patients with the disease of the vitreoretinal interface compared to adult vitreoretinal surgery and some critical points for this surgery.